Vectors for DNA immunization against cervical cancer

• US 6,235,523 B1
• Filed: 09/03/1999
• Issued: 05/22/2001
• Est. Priority Date: 09/04/1998
• Status: Expired due to Term

• Current Assignee: Connaught Laboratories Limited
• Original Assignee: Connaught Laboratories Limited
• Inventors: Gajewczyk, Diane M., Moingeon, Phillipe, Cao, Shi-Xian, Tartaglia, James, Klein, Michel H., Rovinski, Benjamin, Persson, Roy, Yao, Fei-Long
• Primary Examiner(s): Hauda, Karen M.
• Assistant Examiner(s): Nguyen, Quang
• Application Number:
  US09/390,027
• Time in Patent Office: 627 Days
• Field of Search: 435/320.1, 514/44, 424/93.2, 424/192.1, 424/204.1, 424/186.1, 536/23.72, 536/24.3
• US Class Current: 435/320.1
• CPC Class Codes: A61B 5/0263 using NMR
• CPC Class Codes: A61B 5/029 Measuring or recording blood output from the heart, e.g. minute volume A61B8/065 takes precedence
• CPC Class Codes: A61B 5/055 involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• CPC Class Codes: A61B 5/41 Detecting, measuring or recording for evaluating the immune or lymphatic systems
• CPC Class Codes: A61K 2039/51 comprising whole cells, viruses or DNA/RNA
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 2710/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2710/20043 viral genome or elements thereof as genetic vector
• CPC Class Codes: Y10S 977/804 Containing nucleic acid
• CPC Class Codes: Y10S 977/904 for medical, immunological, body treatment, or diagnosis
• CPC Class Codes: Y10S 977/916 Gene therapy
• CPC Class Codes: Y10S 977/924 using nanostructure as support of dna analysis

Abstract

Vectors for DNA immunization against cervical cancer comprise a nucleic acid molecule encoding at least one non-toxic T-cell epitope of the E6 and/or E7 antigens of a strain of human papilloma virus (HPV) associated with cervical cancer, such as HPV-16, and a promoter operatively coupled to the nucleic acid molecule for expression of the nucleic acid molecule in a host to which the vector is administered.

Claims

1. A vector comprising a nucleic acid molecule encoding an HPV-16 E7 antigen lacking amino acids 21-26, wherein said nucleic acid molecule is operatively linked to a cytomegalovirus promoter.

2. The vector of claim 1 wherein said nucleic acid molecule is inserted into plasmid CMV-3.

3. The vector of claim 1 wherein said vector is pCMV-dE7.

4. A vector comprising a nucleic acid molecule encoding HPV-16 E7 antigen epitopes consisting of amino acids 11 to 20, 49 to 57, 82 to 90 and 86 to 93 and an HPV-16 E6 antigen epitope consisting of amino acids 29 to 38, wherein said nucleic acid molecule is operatively linked to a cytomegalovirus promoter.

5. The vector of claim 4 wherein said nucleic acid molecule consists of SEQ ID No:

4 or 5.

6. The vector of claim 4 wherein said nucleic acid molecule encodes an amino acid sequence consisting of SEQ ID No:

6.

7. The vector of claim 4 wherein said vector is pCMV3-HPVT#1.